CtBP1 Antibody [J24B2] | Primary Antibodies

Application: Reactivity: Human

Lane 1: SH-SY5Y, Lane 2: Raji, Lane 3: A549, Lane 4: Hela

Usage Information

Dilution
WB1:1000-1:10000 IHC1:100-1:250 IF1:100-1:250 FCM1:2000

Application
WB, IHC, IF, FCM

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
47 kDa 48 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
CtBP1 Antibody [J24B2] detects endogenous levels of total CtBP1 protein.

Clone
J24B2

Synonym(s)
CTBP; CTBP1; C-terminal-binding protein 1; CtBP1

Background
CtBP1 (C‑terminal‑binding protein 1) is a transcriptional corepressor and NAD‑dependent dehydrogenase that belongs to the CtBP family alongside its close homologue CtBP2 and is widely expressed in tissues involved in development, metabolism, and epithelial homeostasis. It contains conserved NAD‑binding and substrate‑binding domains that couple its enzymatic activity to the cellular redox state, with NADH levels influencing its conformation and interaction with partner proteins, and features dimerization and multimerization interfaces that support assembly of larger repressor complexes with other transcriptional regulators. CtBP1 binds a broad set of transcriptional repressors that contain PXDLS‑like motifs, including PRDM16, Snail family factors, and other zinc‑finger‑containing regulators, and functions within complexes that recruit histone deacetylases and other chromatin‑modifying enzymes to target gene promoters. CtBP1 interacts with PRDM16 and C/EBPα‑linked regulatory circuits that repress white‑fat‑associated genes and influence the brown‑fat differentiation program, positioning it as a redox‑sensitive component of adipogenic identity and energy‑balance signaling. CtBP1 regulates epithelial and tumor‑suppressor loci, including Brca1 and E‑cadherin, whose promoters are bound by CtBP1‑containing complexes so that elevated CtBP1 activity correlates with transcriptional downregulation of these genes and reduced epithelial integrity. In breast and other carcinomas, nuclear CtBP1 is frequently detected at elevated levels and is associated with reduced Brca1 and E‑cadherin expression, increased cell migration, and more aggressive disease phenotypes.

Background

CtBP1 (C‑terminal‑binding protein 1) is a transcriptional corepressor and NAD‑dependent dehydrogenase that belongs to the CtBP family alongside its close homologue CtBP2 and is widely expressed in tissues involved in development, metabolism, and epithelial homeostasis. It contains conserved NAD‑binding and substrate‑binding domains that couple its enzymatic activity to the cellular redox state, with NADH levels influencing its conformation and interaction with partner proteins, and features dimerization and multimerization interfaces that support assembly of larger repressor complexes with other transcriptional regulators. CtBP1 binds a broad set of transcriptional repressors that contain PXDLS‑like motifs, including PRDM16, Snail family factors, and other zinc‑finger‑containing regulators, and functions within complexes that recruit histone deacetylases and other chromatin‑modifying enzymes to target gene promoters. CtBP1 interacts with PRDM16 and C/EBPα‑linked regulatory circuits that repress white‑fat‑associated genes and influence the brown‑fat differentiation program, positioning it as a redox‑sensitive component of adipogenic identity and energy‑balance signaling. CtBP1 regulates epithelial and tumor‑suppressor loci, including Brca1 and E‑cadherin, whose promoters are bound by CtBP1‑containing complexes so that elevated CtBP1 activity correlates with transcriptional downregulation of these genes and reduced epithelial integrity. In breast and other carcinomas, nuclear CtBP1 is frequently detected at elevated levels and is associated with reduced Brca1 and E‑cadherin expression, increased cell migration, and more aggressive disease phenotypes.

References
https://pubmed.ncbi.nlm.nih.gov/21681822/ https://pubmed.ncbi.nlm.nih.gov/20818429/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%